CD8A and malignant colon neoplasm: In this study, we demonstrated that lenalidomide can be used as a potential immunomodulatory drug with tumor antigen-loaded DCs in a colon cancer model, augmenting the ability of DC immunization to enhance the magnitude and function of tumor antigen-specific effector CD8+ T cells, while also amplifying NK cell function and number.